Compass Therapeutics
CMPXCMPX · Stock Price
Historical price data
Overview
Compass Therapeutics is a public, clinical-stage biotech focused on developing sophisticated antibody-based immunotherapies for cancer. The company's strategy centers on leveraging its proprietary technology platforms to rapidly generate diverse therapeutic candidates designed to modulate the tumor microenvironment and coordinate a comprehensive immune attack. With a market cap of approximately $930M, Compass is advancing a pipeline of novel agents, with its lead candidate, tovecimig, in clinical development, aiming to address significant unmet needs in oncology.
Technology Platform
Proprietary discovery and optimization platforms designed for rapid identification of diverse therapeutic antibody leads with a focus on modulating the tumor microenvironment and bridging innate and adaptive immunity.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| CTX-009 + Paclitaxel | Biliary Tract Cancer | Phase 2/3 | |
| CTX-009 | Metastatic Colorectal Cancer | Phase 2 | |
| CTX-009 + CTX-471 | Glioblastoma | Phase 1/2 | |
| Gemcitabine + Cisplatin + Durvalumab + CTX-009 | Metastatic Biliary Tract Cancer | Phase 1/2 | |
| CTX-009 (ABL001) + Paclitaxel + Irinotecan | P1b: Advanced Solid Tumors | Phase 1/2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Compass competes in the crowded antibody and immuno-oncology space against numerous clinical-stage biotechs and large pharma. Differentiation hinges on proving the novelty and clinical superiority of its 'immune bridge' mechanism and the productivity of its discovery platform. Success likely requires strategic partnerships for later-stage development.